ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.

被引：1
|
作者：
Bouzyk, M.
Gray, K. P.
Regan, M. M.
Pagani, O.
Tang, W.
Kammler, R.
Maibach, R.
Viale, G.
Dell'Orto, P.
Thurlimann, B. J. K.
Hitre, E.
Lyng, M.
Ditzel, H. J.
Neven, P.
MacGrogan, G.
Price, K. N.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
Leyland-Jones, B.
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] IBCSG Stat Ctr, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[5] Emory Biomarker Serv Ctr, Atlanta, GA USA
[6] IBCSG Cent Pathol Off, Milan, Italy
[7] IBCSG Coordinating Ctr, Bern, Switzerland
[8] European Inst Oncol, Milan, Italy
[9] Kantonsspital, St Gallen, Switzerland
[10] Natl Inst Oncol, Budapest, Hungary
[11] Univ Southern Denmark, Odense, Denmark
[12] Odense Univ Hosp, DK-5000 Odense, Denmark
[13] UZ Leuven, Louvain, Belgium
[14] Inst Bergonie, Bordeaux, France
[15] Univ Sydney, Sydney, NSW 2006, Australia
[16] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [21] DESIGN AND EVOLUTION OF BIG 1-98: A RANDOMIZED, DOUBLE-BLIND, PHASE-III STUDY COMPARING LETROZOLE AND TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE, EARLY BREAST CANCER - BIG 1-98 COLLABORATIVE AND INTERNATIONAL BREAST CANCER STUDY GROUPS
    Giobbie-Hurder, A. E.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
  • [22] Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis
    Thuerlimann, B.
    BREAST, 2009, 18 : S60 - S60
  • [23] Five years of continuous letrozole versus tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer:: Further analyses and update of BIG 1-98
    Coates, Alan S.
    Keshaviah, Aparna
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Paridaens, Robert
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Smith, Ian
    Goldhirsch, Aron
    ANNALS OF ONCOLOGY, 2006, 17 : 93 - 94
  • [24] Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India
    Chattopadhyay, Shilpi
    Siddiqui, Sarah
    Akhtar, Md. Salman
    Najm, Mohammad Zeeshan
    Deo, S. V. S.
    Shukla, N. K.
    Husain, Syed Akhtar
    TUMOR BIOLOGY, 2014, 35 (05) : 4517 - 4527
  • [25] BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
    Mouridsen, H. T.
    Keshaviah, A.
    Mauriac, L.
    Forbes, J.
    Paridaens, R.
    Castiglione-Gertsch, M.
    Gelber, R.
    Smith, I.
    Thuerlimann, B.
    Goldhirsch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 10S - 10S
  • [26] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
    Coates, Alan S.
    Keshaviah, Aparna
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Del Mastro, Lucia
    Smith, Ian
    Chirgwin, Jacquie
    Nogaret, Jean-Marie
    Pienkowski, Tadeusz
    Wardley, Andrew
    Jakobsen, Erik H.
    Price, Karen N.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 486 - 492
  • [27] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    Alkner, S.
    Jensen, M. -B.
    Rasmussen, B. B.
    Bendahl, P. -O.
    Ferno, M.
    Ryden, L.
    Mouridsen, H.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 481 - 490
  • [28] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    S. Alkner
    M.-B. Jensen
    B. B. Rasmussen
    P.-O. Bendahl
    M. Fernö
    L. Rydén
    H. Mouridsen
    Breast Cancer Research and Treatment, 2017, 166 : 481 - 490
  • [29] BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
    Thurlimann, BJ
    Keshaviah, A
    Mouridsen, H
    Mauriac, L
    Forbes, JF
    Paridaens, R
    Castiglione-Gertsch, M
    Gelber, RD
    Smith, I
    Goldhirsch, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 6S - 6S
  • [30] CYP2D6 and ESR genotypes in adjuvant tamoxifen treatment for early breast cancer.
    Kim, K.
    Jung, K. H.
    Ahn, J.
    Kim, S.
    Kim, H. J.
    Ko, B.
    Lee, J. W.
    Son, B. H.
    Ahn, S.
    Gong, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345